Swiss drugmaker Sandoz aims to more than double its annual net sales by 2035, with a majority coming from biosimilar medicines, the company said at its capital markets day on Tuesday.
Biosimilars are biological drugs based on existing medicines for which patents have expired. Like generics, they are usually sold at much cheaper prices than patented drugs, as they do not have to factor in significant research and development costs.
